Spots Global Cancer Trial Database for ovarian cancer stage iii
Every month we try and update this database with for ovarian cancer stage iii cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer | NCT04701645 | Ovarian Cancer Fallopian Tube ... Peritoneal Canc... Ovarian Cancer ... Ovarian Cancer ... Fallopian Tube ... Fallopian Tube ... | Microdevice | 18 Years - | Dana-Farber Cancer Institute | |
| PARP Inhibitor Oral Maintenance in Low-Risk Ovarian Cancer | NCT05187208 | Epithelial Ovar... Ovarian Cancer Ovarian Cancer ... Ovarian Cancer ... | Niraparib | 20 Years - | Seoul National University Hospital | |
| Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy | NCT06268665 | Breast Cancer Breast Cancer S... Breast Cancer S... Breast Cancer S... Breast Cancer S... Invasive Breast... Ovarian Cancer Ovarian Cancer ... Ovarian Cancer ... Ovarian Cancer ... Ovarian Cancer ... Ovarian Cancer ... Ovarian Cancer ... Ovarian Cancer ... Ovarian Cancer ... Ovarian Cancer ... Ovarian Cancer ... Ovarian Cancer ... Breast Cancer S... Breast Cancer I... Breast Cancer, ... Breast Cancer, ... Breast Cancer S... Breast Cancer S... Breast Cancer S... Breast Cancer S... Cancer, Breast Tumors, Breast Mammary Cancer Mammary Carcino... Breast Carcinom... Breast Neoplasm Malignant Breas... Malignant Tumor... Cancer of Ovary Ovary Cancer Ovary Neoplasm | Tart Cherry Jui... | 18 Years - | University of California, Davis | |
| The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer | NCT03162562 | Cancer of Ovary Neoplasms, Ovar... Ovarian Cancer ... Ovarian Cancer ... Ovarian Cancer ... Ovary Cancer | Oregovomab Poly ICLC | 18 Years - 90 Years | CanariaBio Inc. | |
| Self-Advocacy Serious Game in Advanced Cancer | NCT03339765 | Ovarian Cancer ... Ovarian Cancer ... Breast Cancer S... Cervical Cancer... Cervical Cancer... Cervical Cancer... Endometrial Can... Endometrial Can... Vulvar Cancer, ... Vulvar Cancer, ... Vaginal Cancer ... Vaginal Cancer ... Vaginal Cancer ... | Strong Together... | 18 Years - | University of Pittsburgh | |
| Dynamic Monitoring of ctDNA Predicts Recurrence of Advanced Ovarian Cancer After Primary Treatments | NCT06025045 | Ovarian Cancer ... Ovarian Cancer ... | 18 Years - | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | ||
| Tumor Microenvironment in Ovarian Cancer | NCT06272240 | Ovarian Cancer ... Ovarian Cancer ... | Ovarian Cancer ... | 18 Years - 80 Years | University of Udine | |
| Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer | NCT04938583 | Ovarian Cancer ... Ovarian Cancer ... Ovarian Cancer ... | Oregovomab Bevacizumab Paclitaxel Carboplatin | 19 Years - | CanariaBio Inc. | |
| A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients | NCT05479045 | Ovarian Cancer ... Ovarian Cancer ... Ovarian Cancer ... | NY-ESO-1 Peptid... Nivolumab | 18 Years - | Georgetown University | |
| The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer | NCT03162562 | Cancer of Ovary Neoplasms, Ovar... Ovarian Cancer ... Ovarian Cancer ... Ovarian Cancer ... Ovary Cancer | Oregovomab Poly ICLC | 18 Years - 90 Years | CanariaBio Inc. | |
| Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer | NCT04938583 | Ovarian Cancer ... Ovarian Cancer ... Ovarian Cancer ... | Oregovomab Bevacizumab Paclitaxel Carboplatin | 19 Years - | CanariaBio Inc. | |
| Prehabilitation in Gynaecological Cancer Patients | NCT04789694 | Ovarian Cancer Ovarian Cancer ... Ovarian Cancer ... Endometrial Can... Frailty | Physiological i... Psychological i... Nutritional int... | 18 Years - 85 Years | Charles University, Czech Republic | |
| Prehabilitation in Gynaecological Cancer Patients | NCT04789694 | Ovarian Cancer Ovarian Cancer ... Ovarian Cancer ... Endometrial Can... Frailty | Physiological i... Psychological i... Nutritional int... | 18 Years - 85 Years | Charles University, Czech Republic | |
| Predicting Outcome of Cytoreduction in Advanced Ovarian Cancer, Using a Machine Learning Algorithm and Patterns of Disease Distribution at Laparoscopy (PREDAtOOR) | NCT06017557 | Ovarian Cancer ... Ovarian Cancer ... | Artificial Inte... | 18 Years - | University Health Network, Toronto | |
| Tumor Microenvironment in Ovarian Cancer | NCT06272240 | Ovarian Cancer ... Ovarian Cancer ... | Ovarian Cancer ... | 18 Years - 80 Years | University of Udine | |
| Predicting Outcome of Cytoreduction in Advanced Ovarian Cancer, Using a Machine Learning Algorithm and Patterns of Disease Distribution at Laparoscopy (PREDAtOOR) | NCT06017557 | Ovarian Cancer ... Ovarian Cancer ... | Artificial Inte... | 18 Years - | University Health Network, Toronto |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
